MMWR Morbidity and Mortality Weekly Report · 2021 · 11 citations · 5 references
Veterinary MedicineInfectious Disease ControlInfectious DiseasesOutbreak InvestigationPublic Health SurveillanceVirologyAntigen Detection AssaysInfectious Disease Molecular TestingInfectious Disease ScreeningMolecular SurveillanceRapid Diagnostic TestsSerological DiagnosticsPoint-of-care Antigen TestingRapid Antigen Detection TestingRapid Antigen TestingRapid Antigen TestsRapid Serological TestsSars-cov-2 InfectionSerological Rapid TestsViral Serology Screening
Controlling the spread of SARS-CoV-2, the virus that causes COVID-19, in Alaska is challenging. Alaska includes many remote and isolated villages with small populations (ranging from 15 to >1,000 persons) that are accessible only by air from larger communities. Until rapid point-of-care testing became widely available, a primary challenge in the diagnosis of COVID-19 in rural Alaska was slow turnaround times for SARS-CoV-2 test results, attributable to the need to transport specimens to testing facilities. To provide more timely test results and isolation of cases, the Yukon Kuskokwim Health Corporation (YKHC) introduced Abbott BinaxNOW COVID-19 Ag rapid antigen test (BinaxNOW) on November 9, 2020, in the rural Yukon-Kuskokwim Delta region in southwestern Alaska. To evaluate the impact of implementing antigen testing, YKHC reviewed the results of 54,981 antigen and molecular tests for SARS-CoV-2 performed in the Yukon-Kuskokwim Delta during September 15, 2020-March 1, 2021. Introduction of rapid, point-of-care testing was followed by a more than threefold reduction in daily SARS-CoV-2 case rates during approximately 1 month before the introduction of COVID-19 vaccination. The median turnaround time for SARS-CoV-2 test results decreased by >30%, from 6.4 days during September 15-November 8, 2020, to 4.4 days during November 9, 2020-March 1, 2021 (p<0.001). Daily incidence decreased 65% after the introduction of BinaxNOW, from 342 cases per 100,000 population during the week of November 9 to 119 during the week of December 13 (p<0.001). These findings indicate that point-of-care rapid antigen testing can be a valuable tool in reducing turnaround times in rural communities where local access to laboratory-based nucleic acid amplification testing (NAAT) is not readily available and could thereby reduce transmission by facilitating rapid isolation of infected persons, contact tracing, and implementation of local mitigation strategies.
5
Provisional Mortality Data — United States, 2020
Farida Ahmad, Jodi A. Cisewski, Arialdi Miniño et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 323 citations · Full text
Jessica L. Prince-Guerra, Olivia Almendares, Leisha D. Nolen et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 252 citations · Full text
COVID-19 Among American Indian and Alaska Native Persons — 23 States, January 31–July 3, 2020
Sarah M. Hatcher, Christine Agnew-Brune, Mark S. Anderson et al. · MMWR Morbidity and Mortality Weekly Report · 2020 · 230 citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +11
Thomas W. Hennessy, Troy Ritter, Robert C. Holman et al. · American Journal of Public Health · 2008 · 218 citations · Full text